Hester Biosciences Limited (HESTERBIO.BO)
INR 1693.5
(2.36%)
INR 1693.5
(2.36%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.29 Billion INR | -12.4% |
| 2022 | 2.61 Billion INR | 28.25% |
| 2021 | 2.03 Billion INR | 128.56% |
| 2020 | 892.09 Million INR | -13.21% |
| 2019 | 1.02 Billion INR | 108.91% |
| 2018 | 492.02 Million INR | -11.67% |
| 2017 | 557.02 Million INR | 1.31% |
| 2016 | 549.84 Million INR | 1.9% |
| 2015 | 539.6 Million INR | 19.15% |
| 2014 | 452.86 Million INR | 12.08% |
| 2013 | 404.04 Million INR | 48.73% |
| 2012 | 271.66 Million INR | 163.24% |
| 2011 | 103.2 Million INR | -47.7% |
| 2010 | 197.31 Million INR | -2.07% |
| 2009 | 201.48 Million INR | 7.37% |
| 2008 | 187.66 Million INR | -6.83% |
| 2007 | 201.42 Million INR | -9.91% |
| 2006 | 223.57 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.25 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 2.29 Billion INR | -12.4% |
| 2023 Q4 | 2.29 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 2.6 Billion INR | 0.0% |
| 2022 Q2 | 2.49 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.61 Billion INR | 0.0% |
| 2022 FY | 2.61 Billion INR | 28.25% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 2.03 Billion INR | 128.56% |
| 2021 Q2 | 1 Billion INR | 0.0% |
| 2021 Q4 | 2.03 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 912 Million INR | 0.0% |
| 2020 Q4 | 892.09 Million INR | 0.0% |
| 2020 FY | 892.09 Million INR | -13.21% |
| 2019 FY | 1.02 Billion INR | 108.91% |
| 2019 Q4 | 1.02 Billion INR | 0.0% |
| 2019 Q2 | 532.91 Million INR | 0.0% |
| 2018 FY | 492.02 Million INR | -11.67% |
| 2018 Q4 | 492.02 Million INR | 0.0% |
| 2017 FY | 557.02 Million INR | 1.31% |
| 2016 FY | 549.84 Million INR | 1.9% |
| 2015 FY | 539.6 Million INR | 19.15% |
| 2014 FY | 452.86 Million INR | 12.08% |
| 2013 FY | 404.04 Million INR | 48.73% |
| 2012 Q4 | 271.66 Million INR | 0.0% |
| 2012 FY | 271.66 Million INR | 163.24% |
| 2012 Q2 | 74.44 Million INR | 0.0% |
| 2011 FY | 103.2 Million INR | -47.7% |
| 2010 FY | 197.31 Million INR | -2.07% |
| 2009 FY | 201.48 Million INR | 7.37% |
| 2008 FY | 187.66 Million INR | -6.83% |
| 2007 FY | 201.42 Million INR | -9.91% |
| 2006 FY | 223.57 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 40.745% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 37.976% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 180.584% |
| Granules India Limited | 9.28 Billion INR | 75.333% |
| Indoco Remedies Limited | 6.47 Billion INR | 64.629% |
| Achyut Healthcare Limited | -3.74 Million INR | 61251.628% |
| Ajanta Pharma Limited | -954.9 Million INR | 339.893% |
| Alkem Laboratories Limited | -1.6 Billion INR | 242.335% |
| Alpa Laboratories Limited | 35.36 Million INR | -6377.788% |
| Brooks Laboratories Limited | 49.48 Million INR | -4529.16% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 145.701% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 30.562% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 297.861% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 82.26% |
| Eris Lifesciences Limited | 13.8 Billion INR | 83.408% |
| FDC Limited | -57.75 Million INR | 4066.512% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 153.456% |
| Gufic Biosciences Limited | 3.19 Billion INR | 28.287% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 155.158% |
| Ipca Laboratories Limited | 11.41 Billion INR | 79.933% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 264.81% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -18.512% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1013.096% |
| Laurus Labs Limited | 24.38 Billion INR | 90.606% |
| Lupin Limited | 17.19 Billion INR | 86.676% |
| Mankind Pharma Limited | -9.9 Billion INR | 123.12% |
| Medicamen Biotech Limited | 160.31 Million INR | -1328.89% |
| Medico Remedies Limited | 78.67 Million INR | -2811.575% |
| Megasoft Limited | 1.28 Billion INR | -78.191% |
| NATCO Pharma Limited | -5.81 Billion INR | 139.38% |
| Piramal Pharma Limited | 42.27 Billion INR | 94.581% |
| RPG Life Sciences Limited | -364.7 Million INR | 728.116% |
| Sigachi Industries Limited | 859.94 Million INR | -166.381% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 103.161% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -1480.082% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -4857.131% |
| Unichem Laboratories Limited | 931.91 Million INR | -145.81% |
| Wanbury Limited | 1.1 Billion INR | -107.143% |
| Windlas Biotech Limited | -273.04 Million INR | 938.976% |
| ZIM Laboratories Limited | 983.6 Million INR | -132.893% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 41.443% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 343.23% |
| Divi's Laboratories Limited | -39.77 Billion INR | 105.76% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 197.561% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1020.745% |
| Bal Pharma Limited | 1.26 Billion INR | -81.292% |
| Strides Pharma Science Limited | 23.25 Billion INR | 90.15% |
| Venus Remedies Limited | -267.7 Million INR | 955.712% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 12.296% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 62.796% |
| Shilpa Medicare Limited | 9.06 Billion INR | 74.742% |
| Aarti Drugs Limited | 5.54 Billion INR | 58.714% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 308.003% |
| Suven Life Sciences Limited | -1.63 Billion INR | 240.304% |
| Ind-Swift Limited | 9.5 Billion INR | 75.909% |
| Valiant Laboratories Limited | -295.03 Million INR | 876.438% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 18.803% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 77.159% |
| Themis Medicare Limited | 764.96 Million INR | -199.458% |
| Hikal Limited | 7.96 Billion INR | 71.247% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 92.803% |
| Sequent Scientific Limited | 4.17 Billion INR | 45.18% |
| Novartis India Limited | -5.89 Billion INR | 138.885% |
| Wockhardt Limited | 18.27 Billion INR | 87.462% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 91.538% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 12518.627% |
| Neuland Laboratories Limited | -214.05 Million INR | 1170.149% |
| Morepen Laboratories Limited | -231.17 Million INR | 1090.916% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -1808.33% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -134.752% |